Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 22;12(8):6536-6542.
doi: 10.18632/aging.103102. Epub 2020 Apr 22.

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

Libo Zhang  1 , Rongrong Pang  1 , Xiang Xue  2 , Jingjing Bao  1 , Sheng Ye  3 , Yudong Dai  4 , Yishan Zheng  5 , Qiang Fu  4 , Zhiliang Hu  6   7 , Yongxiang Yi  6
Affiliations

Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19

Libo Zhang et al. Aging (Albany NY). .

Abstract

Background: Anti-SARS-CoV-2 virus antibody levels in convalescent plasma (CP), which may be useful in severe Anti-SARS-CoV-2 virus infections, have been rarely reported.

Results: A total of eight donors were considered for enrollment; two of them were excluded because of ineligible routine check. Of the six remaining participants, five samples were tested weakly positive by the IgM ELISA. Meanwhile, high titers of IgG were observed in five samples. The patient treated with CP did not require mechanical ventilation 11 days after plasma transfusion, and was then transferred to a general ward.

Conclusions: Our serological findings in convalescent plasma from recovered patients may help facilitate understanding of the SARS-CoV-2 infection and establish CP donor screening protocol in COVID-19 outbreak.

Methods: Anti-SARS-CoV-2 antibodies including IgM and IgG were measured by two enzyme-linked immunosorbent assays (ELISA) in convalescent plasma from six donors who have recovered from coronavirus disease 2019 (COVID-19) in Nanjing, China. CP was also utilized for the treatment of one severe COVID-19 patient.

Keywords: COVID-19; SARS-CoV-2 virus; anti-SARS-CoV-2 antibodies; convalescent plasma; coronavirus disease 2019; plasma donation.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors declare that they have no conflicts of interests.

Figures

Figure 1
Figure 1
Specific immunoglobulin IgG were titrated by semiquantitative ELISA. Plasma IgG antibody titers ranged from 1:40 to >320.
See this image and copyright information in PMC

References

    1. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020; 25:278–80. 10.1111/tmi.13383 - DOI - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323:1239. 10.1001/jama.2020.2648 - DOI - PubMed
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20:398–400. 10.1016/S1473-3099(20)30141-9 - DOI - PMC - PubMed
    1. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020; 92:479–90. 10.1002/jmv.25707 - DOI - PMC - PubMed
    1. Garraud O. Use of convalescent plasma in Ebola virus infection. Transfus Apher Sci. 2017; 56:31–34. 10.1016/j.transci.2016.12.014 - DOI - PubMed